The Relationship Between Serum Orexin A, TGF-β, and Leptin Levels with Body Mass Index in Multiple Sclerosis Patients

2021 ◽  
Author(s):  
Sepideh Moharami ◽  
Alireza Nourazarian ◽  
Masoud Nikanfar ◽  
Delara Laghousi ◽  
behrouz shademan ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Serum Level ◽  
Serum Levels ◽  
Healthy Controls ◽  
Control Groups ◽  
Orexin A ◽  
The Mean ◽  
Multiple Sclerosis Patients ◽  
And Control ◽  
The Relationship

Abstract Backgrounds: Multiple Sclerosis (MS) is a chronic inflammatory and autoimmune disease linked to several inflammatory and dietary parameters. This study was carried out to determine the relationship between serum leptin, orexin-A, and TGF-β levels with BMI in MS patients.Methods and results: In this cross-sectional study, 25 relapsing-remitting multiple sclerosis (RRMS) patients and 40 healthy controls were enrolled. The serum level of Leptin, Orexin-A, and TGF- were measured by the Enzyme-linked immunosorbent assay (ELISA). The data was analyzed using descriptive statistics, t-test, Chi-square test, and Linear regression test. A total of 65 volunteers, including 25 MS patients and 40 healthy, were enrolled in the study. The mean age of individuals in the case and control groups was 38.04 ± 7.53 and 40.23 ± 5.88. There were no statistically significant differences between the case and control groups regarding gender, age, alcohol, and cigarette use (P>0.05). The mean serum levels of Orexin-A and TGF-ß were lower among multiple sclerosis patients than in healthy controls, but leptin was higher (42.8 vs. 18.9 ng/ml, P<0.001). The relationship between BMI and serum levels of Orexin-A, TGF-ß, and Leptin among Multiple Sclerosis patients was not statistically significant (P > 0.05).Conclusion: Our results showed that the serum levels of Orexin-A and TGF-β were significantly lower. The serum level of leptin was higher among multiple sclerosis patients than among healthy controls. Also, there was no statistically significant relationship between BMI and serum levels of Orexin-A, TGF-ß, and Leptin among multiple sclerosis patients.

scholarly journals Reduction in circulating vitamin D binding protein in patients with multiple sclerosis

BMC Neurology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Zhila Maghbooli ◽  
Abolfazl Omidifar ◽  
Tarlan Varzandi ◽  
Tayebeh Salehnezhad ◽  
Mohammad Ali Sahraian
Keyword(s):  
Multiple Sclerosis ◽  
Vitamin D ◽  
Binding Protein ◽  
Serum Levels ◽  
Causative Role ◽  
Vitamin D Binding Protein ◽  
Control Groups ◽  
Current Case ◽  
Vitamin D Levels ◽  
And Control

Abstract Background In this study, we aimed to determine the risk association between vitamin D binding protein (VDBP) polymorphism in patients with multiple sclerosis (MS) in a MS biobank and the difference in VDBP serum levels in MS patients who were recently diagnosed. Method The current case-control study was performed on 296 MS patients and 313 controls. Thereafter, two common missense VDBP polymorphisms, named rs7041and rs4588, were evaluated in all the participants. Serum levels of vitamin D and vitamin D binding protein were assessed in 77 MS patients who were diagnosed since one year ago and in 67 healthy people who were matched in terms of age and sex. Result The frequency distributions of VDBP genotypes and alleles of SNP rs7041 and rs4588 were observed to be similar in both the MS and control groups (p > 0.05). The VDBP haplotypes, as Gc2/Gc2, Gc1/Gc1, and Gc1/Gc2, were found to be similar in the MS and control groups (p > 0.05). In subgroup analysis, circulating VDBP was lower in MS patients (Ln-VDBP (μgr/ml): 3.64 ± 0.91 vs. 5.31 ± 0.77, p = 0.0001) even after adjusting for vitamin D levels, body mass index, and taking vitamin D supplement. There was no significant association between VDBP haplotypes and vitamin D levels in the two groups. Conclusion The present study suggested an association between lower levels of circulating VDBP and multiple sclerosis in newly diagnosed patients. However, the VDBP causative role in the development of MS is still unclear, so it needs more studies.

Plasma kisspeptin and ghrelin levels in puberty variant cases

2017 ◽  
Vol 30 (5) ◽  
Author(s):  
Erdal Kurnaz ◽  
Yaşar Şen ◽  
Süleyman Aydın
Keyword(s):  
Serum Levels ◽  
Control Group ◽  
Control Groups ◽  
Premature Thelarche ◽  
Premature Adrenarche ◽  
Significant Difference ◽  
And Gender ◽  
And Control ◽  
Relationship Of ◽  
The Relationship

AbstractBackground:The aim of this study was to determine the serum levels of kisspeptin and ghrelin (GAH), as well as the relationship of these two peptides with each other in premature thelarche (PT) and premature adrenarche (PA) cases and to investigate the possibility of using these peptides as markers in the differentiation of puberty disorders.Methods:A PT group aged 1–8 years (n = 40), a PA group aged 1–9 years (n = 23, female/male = 20/3) and control groups consistent with each of the previous groups in terms of age and gender were created for the study. Kisspeptin and ghrelin levels were measured with ELISA methods from blood samples drawn while fasting in the morning.Results:When the PT group was compared with the controls, the plasma kisspeptin levels of the cases were significantly higher than the control group (165.47 ± 15.45 pmol/L, 96.82 ± 12.33 pmol/L, p = 0.005, respectively). Kisspeptin levels in the PA group did not show a difference with the control group (121.36 ± 17.99 pmol/L, 95.52 ± 11.54 pmol/L, p = 0.249, respectively). No significant difference could be found when GAH levels in the PT and PA groups were compared with controls. No significant correlation was found between kisspeptin and GAH levels in the PT and PA groups.Conclusions:Our results indicate that kisspeptin plays an important role in the PT, but GAH is not associated with puberty disorders.

Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome

2006 ◽  
Vol 291 (2) ◽  
pp. R277-R284 ◽  
Author(s):  
Lin Chang ◽  
Emeran A. Mayer ◽  
Jennifer S. Labus ◽  
Max Schmulson ◽  
Oh Young Lee ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Sigmoid Colon ◽  
Healthy Controls ◽  
Perceptual Sensitivity ◽  
Control Groups ◽  
Healthy Men ◽  
Before And After ◽  
Irritable Bowel ◽  
And Control ◽  
The Relationship

In irritable bowel syndrome (IBS) patients, the relationship between sex and sensitivity to visceral stimuli is incompletely understood. Our aim was to evaluate the effect of sex on perceptual responses to visceral stimulation in IBS. Fifty-eight IBS patients (mean age 42 ± 1 yr; 34 men, 24 women) and 26 healthy controls (mean age 38 ± 3 yr; 9 men, 17 women) underwent barostat-assisted distensions of the rectum and sigmoid colon. Rectal discomfort thresholds were measured using a randomized, phasic distension paradigm before and after repeated noxious sigmoid stimulation (SIG, 60-mmHg pulses). Sex had a significant effect on rectal discomfort thresholds. Women with IBS were the most sensitive (lower thresholds [27 ± 2.7 mmHg] and higher ratings), with significantly lower rectal discomfort thresholds compared with men with IBS (38 ± 2.3 mmHg) and healthy women who were the least sensitive (41.9 ± 3.2 mmHg; both P < 0.01). There were no significant differences in rectal discomfort thresholds between healthy men (34 ± 4.3 mmHg) and men with IBS. Across both IBS and control groups, women demonstrated a significant lowering of discomfort thresholds after noxious sigmoid stimulation ( P < 0.01), while men did not. Sex significantly influences perceptual sensitivity to rectosigmoid distension. Women show greater perceptual responses to this paradigm.

scholarly journals The Assessment of 25-Hydroxy Vitamin D Serum Level in Asthmatic Patients: A Case-Control Study

2017 ◽  
Vol 5 (2) ◽  
pp. 65-69
Author(s):  
Mohammad Rasoul Sharanjani ◽  
Ebrahim Nadi ◽  
Maryam Vasheghani ◽  
Mohammad Jafari ◽  
Jalal Poorolajal
Keyword(s):  
Vitamin D ◽  
Serum Levels ◽  
Control Group ◽  
Control Groups ◽  
Asthmatic Patients ◽  
25 Hydroxy Vitamin D ◽  
The Mean ◽  
25 Oh Vitamin D ◽  
And Control ◽  
Control Study

Background: The prevalence of vitamin D deficiency is increasing due to changes in lifestyle and dietary habits. The aim of this study was to compare the serum levels of 25-hydroxy vitamin D between patients with bronchial asthma and the healthy control group. Patients and Methods: In this case-control study, 45 patients with asthma and 45 healthy subjects were enrolled and the level of serum 25 (OH) vitamin D was measured in both groups. In addition, a welltrained observer assessed airway reversibility, peak flowmetry and spirometry in the participants. The data were statistically analyzed using t test, one-way analysis of variance (ANOVA), and chi-square test with Stata software (version 11). Results: The mean age (±SD) of participants were 49.06 ±16.43 and 46.13 ±16.10 years in case and control groups, respectively (P=.394). The prevalence of vitamin D deficiency was high in both groups (69% in case and 65.5% in control groups). The mean (±SD) serum 25 (OH) vitamin D was 16.24 (±14.98) ng/ml in case group and 17.70 (±16.07) ng/mL in control group (P=.657). We found a positive correlation between the levels of vitamin D and the amount of FEV1 (r=0.2). Conclusions: According to the present study, the mean serum levels of vitamin D differences were not statistically significant between asthmatic patients and control group. However, the results of this study showed a positive relationship between forced expiratory volumes in first second (FEV1) and vitamin D levels

scholarly journals Social support network and quality of life in multiple sclerosis patients

2017 ◽  
Vol 75 (5) ◽  
pp. 267-271 ◽  
Author(s):  
David Castro Costa ◽  
Maria José Sá ◽  
José Manuel Calheiros
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Social Support ◽  
Short Form ◽  
Support Network ◽  
Social Support Network ◽  
The Mean ◽  
Multiple Sclerosis Patients ◽  
The Relationship

ABSTRACT Objective To analyse the relationship between the social support network (SSN) and health related quality of life (HRQOL) in multiple sclerosis (MS) patients. Methods The sample comprised 150 consecutive MS patients attending our MS clinic. To assess the socio-demographic data, a specifically designed questionnaire was applied. The HRQOL dimensions were measured with the Short-Form Health Survey Questionnaire-SF36 and the SSN with the Medical Outcomes Study Social Support Survey. Spearman’s correlation was used to compare the magnitude of the relationship between the SSN and HRQOL. Results The mean patient age was 41.7 years (± 10.4; range: 18–70 yr); the mean Expanded Disability Status Score was 2.5 (±2.4; range: 0–9). There was a statistically significant correlation between the structure of the SSN and the HRQOL. Conclusion The composition of the SSN, social group membership and participation in voluntary work have an important role in the HRQOL of patients with MS.

scholarly journals The Assessment of Serum Concentrations of AGEs and Their Soluble Receptor (sRAGE) in Multiple Sclerosis Patients

2021 ◽  
Vol 11 (8) ◽  
pp. 1021
Author(s):  
Aleksandra Damasiewicz-Bodzek ◽  
Beata Łabuz-Roszak ◽  
Bartłomiej Kumaszka ◽  
Bartosz Tadeusiak ◽  
Krystyna Tyrpień-Golder
Keyword(s):  
Multiple Sclerosis ◽  
Stable Phase ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Healthy Controls ◽  
Soluble Receptor ◽  
Serum Concentrations ◽  
Degree Of Disability ◽  
The Mean ◽  
Multiple Sclerosis Patients

Background: Advanced glycation end products (AGEs) are involved in the pathogenesis of many diseases, including neurodegenerative diseases such as multiple sclerosis (MS). The aim of the study was to determine serum concentrations of AGEs and their soluble receptor (sRAGE) in MS patients and healthy controls and to investigate their possible influence on disease activity. Methods: Serum concentrations of AGE and sRAGE in patients with MS and healthy controls were determined by enzyme-linked immunosorbent assay (ELISA). Results: The mean serum AGE concentration in patients with MS was higher than in healthy controls, whereas the mean serum sRAGE concentration was lower than in the control group. However, the differences were not statistically significant. In MS patients, serum AGE and sRAGE concentrations did not differ significantly, depending on the duration of the disease and the Expanded Disability Status Scale (EDSS) score. Conclusions: Multiple sclerosis may be accompanied by disturbances of the AGE-sRAGE axis. However, further studies are warranted to confirm it. The duration of the disease and the degree of disability do not seem to affect the progression of the glycation process, particularly in the stable phase of the disease.

scholarly journals High prevalence of intrathecal IgA synthesis in multiple sclerosis patients

2021 ◽  
Author(s):  
Ursula Muñoz ◽  
Cristina Sebal ◽  
Esther Escudero ◽  
Maria Isabel García Sánchez ◽  
Elena Urcelay ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Neurological Diseases ◽  
Control Group ◽  
Control Groups ◽  
Serum Samples ◽  
Highly Sensitive ◽  
High Prevalence ◽  
Ultrasensitive Assay ◽  
Multiple Sclerosis Patients ◽  
And Control

Abstract Introduction: The detection of intrathecal IgA synthesis (IAS) in multiple sclerosis (MS) is cumbersome, for this reason, we developed a highly sensitive assay to assess it in MS. Methods: 151 MS patients and 22 controls with different neurological diseases were recruited. IgA concentration was analyzed by ELISA. Oligoclonal IgA bands to detect IAS were determined by a new ultrasensitive assay based on isoelectrofocusing (IEF). Results: Most individuals showed an IgA concentration within normal range in serum samples (95.95%) but 38.41% of individuals had a low IgA concentration in the cerebrospinal fluid (CSF), with no significant differences observed between MS and control groups, neither in CSF nor in serum. The new IEF was more sensitive than those previously described (0.01 mg/dl of IgA), and clearly identified patients with and without IAS, that was not related with IgA concentration. MS patients showed higher percentage of IAS (43.00%) than the control group (18.20) (p = 0.035), because the incidence was especially higher in MS patients with clinically isolated syndrome (CIS, 66.00%). Conclusions: Intrathecal IgA synthesis is observed more frequently in MS patients than in other neurological diseases, and with higher incidence than assumed in the past.

scholarly journals Serum Levels of Growth Differentiation Factor-15 as an Inflammatory Marker in Patients with Unstable Angina Pectoris

2021 ◽  
Author(s):  
Fariba Raygan ◽  
Aniseh Etminan ◽  
Hanieh Mohammadi ◽  
Hossein Akbari ◽  
Hassan Nikoueinejad
Keyword(s):  
Angina Pectoris ◽  
Serum Level ◽  
Unstable Angina ◽  
Serum Levels ◽  
Unstable Angina Pectoris ◽  
Risk Scores ◽  
Growth Differentiation Factor 15 ◽  
Differentiation Factor ◽  
The Mean ◽  
And Control

Background: Growth differentiation factor-15 (GDF-15), a member of transforming growth factors, is a stress-responsive marker whose levels may significantly increase in response to pathological stresses associated with inflammatory tissue injuries such as unstable angina pectoris (USAP). This study evaluated the diagnostic value of GDF-15 in patients with USAP. Methods: The present cross-sectional study recruited 39 patients with USAP criteria and 30 patients with stable angina pectoris (SAP), referred to Shahid Beheshti Hospital, Kashan, Iran. All the patients with USAP had at least 1 coronary artery stenosis (>50%) in angiography. The control group comprised 42 healthy individuals. The serum levels of GDF-15 were measured in all the participants by ELISA. Also analyzed were the relationship between GDF-15 levels and thrombolysis in myocardial infarction (TIMI) and the Global Registry of Acute Coronary Events (GRACE) risk scores in the patients with USAP to determine the severity of the disease. Result: The study population consisted of 111 subjects, 62 women and 49 men, divided into 3 groups of USAP (n=39, mean age=60.07±14.10 y), SAP (n=30, mean age=67.56±9.88 y), and control (n=42, mean age=61.21±7.76 y). The mean serum level of GDF-15 in the USAP group was significantly different from the other 2 groups (P<0.001), while no significant difference was observed in this regard between the SAP and control groups (P=0.797). No correlation was found between the mean GDF-15 serum level and the GRACE (P=0.816) and TIMI (P=0.359) risk scores in the USAP group. Conclusion:  The mean serum level of GDF-15 exhibited a rise in our patients with USAP. GDF-15 may be a diagnostic biomarker of USAP and its severity.

The Matrix Metalloproteinases Panel in Multiple Sclerosis Patients Treated with Natalizumab: A Possible Answer to Natalizumab Non- Responders

2018 ◽  
Vol 17 (6) ◽  
pp. 464-472 ◽  
Author(s):  
Rodica Balasa ◽  
Ciurba Bianca ◽  
Voidezan Septimiu ◽  
Simu Iunius ◽  
Hutanu Adina ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Matrix Metalloproteinases ◽  
Basal Membrane ◽  
Serum Levels ◽  
Healthy Controls ◽  
Lymphocyte Migration ◽  
Relapsing Remitting ◽  
The Matrix ◽  
Edss Score ◽  
Multiple Sclerosis Patients

Background: In the lymphocyte migration across the blood-brain barrier (BBB) in multiple sclerosis (MS), matrix metalloproteinases (MMPs) play an important role in the degradation of the basal membrane. Natalizumab (NAT), a monoclonal antibody, binds to the alpha-4 (α4) integrin leading to BBB impermeability. Approximately 30% of NAT-treated patients show clinical or MRI signs of BBB disruption. Objective: To determine whether NAT significantly influences the MMPs serum levels and to what extent these could be used as biomarkers in relapsing-remitting MS (RRMS) patients. Materials and Methods: This prospective study over a period of 8 months of NAT treatment, included 30 RRMS patients (mean age 38 ± 6 years; mean MS duration 12 ± 5 years), of which ten were initially naive to NAT and 15 were healthy controls. We determined the serum levels of the MMPs Panel (MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP10, MMP12, and MMP13) quantified by a multiplex method at the beginning and end of the study. Results: After 8 months of NAT treatment, a statistically significant decrease was found in MMP9, MMP2, MMP3, MMP8, and MMP10 levels. Relapses during the study were correlated with a variation of MMP12 and MMP13 serum levels. MMP9 had the most numerous correlations with the EDSS score, Rio score, and duration of NAT treatment. MMPs signature (the sum of all MMPs) and the MMP9/MMP2 ratio significantly decreased during the study. Conclusion: 1. The serum level of MMP9 significantly decreased by NAT treatment and correlates with MS activity; 2. After eight months of NAT treatment, the MMPs signature and the MMP9/MMP2 ratio decreased; 3. MMP9 might be used as a biomarker in MS patients treated with NAT.

scholarly journals The expression profile of virus-recognizing toll-like receptors in natural killer cells of Cypriot multiple sclerosis patients

2020 ◽  
Vol 13 (1) ◽  
Author(s):  
Elie Deeba ◽  
Anastasia Lambrianides ◽  
Marios Pantzaris ◽  
George Krashias ◽  
Christina Christodoulou
Keyword(s):  
Risk Factors ◽  
Multiple Sclerosis ◽  
Nk Cells ◽  
Expression Profile ◽  
Genetic Risk ◽  
Viral Infections ◽  
Healthy Controls ◽  
Functional Differences ◽  
Multiple Sclerosis Patients ◽  
And Control

Abstract Objective The exact aetiology of multiple sclerosis (MS) remains elusive, although several environmental and genetic risk factors have been implicated to varying degrees. Among the environmental risk factors, viral infections have been suggested as strong candidates contributing to MS pathology/progression. Viral recognition and control are largely tasked to the NK cells via TLR recognition and various cytotoxic and immunoregulatory functions. Additionally, the complex roles of different TLRs in MS pathology are highlighted in multiple, often contradictory, studies. The present work aims to analyse the TLR expression profile of NK cells isolated from MS patients. Highly purified CD56+CD3− NK cells isolated from peripheral blood of MS patients (n = 19) and healthy controls (n = 20) were analysed via flow cytometry for their expression of viral antigen-recognizing TLRs (TLR2, TLR3, TLR7, and TLR9). Results No difference was noted in TLR expression between MS patients and healthy controls. These results aim to supplement previous findings which study expressional or functional differences in TLRs present in various subsets of the immune system in MS, thus aiding in a better understanding of MS as a complex multifaceted disease.

Sign in / Sign up

Export Citation Format

Share Document